Skip to main content

Heart Transplant clinical trials at UC Health

7 in progress, 3 open to eligible people

Showing trials for
  • Allograft Dysfunction in Heart Transplant

    open to eligible people ages 18 years and up

    The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.

    at UCSD

  • Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

    open to eligible people ages 18 years and up

    Demonstrate the impact of the Molecular Microscope Diagnostic System as the standard of care for heart transplant patients.

    at UCLA

  • Surveillance HeartCare® Outcomes Registry

    open to eligible people ages 15 years and up

    This is an observational registry to assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients.

    at UCSD

  • Donors After Circulatory Death Heart Trial

    Sorry, not currently recruiting here

    To evaluate the effectiveness of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.

    at UCSD

  • Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing

    Sorry, in progress, not accepting new patients

    The objective of this registry is to observe short and long term clinical outcomes in heart transplant recipients who receive regular AlloMap testing as part of allograft rejection surveillance.

    at UCLA

  • Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

    Sorry, in progress, not accepting new patients

    The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).

    at UCLA

  • Tocilizumab in Cardiac Transplantation

    Sorry, not currently recruiting here

    The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.

    at UCLA UCSD

Last updated: